Cargando…

Neoadjuvant targeted therapy for resectable EGFR-mutant non-small cell lung cancer: Current status and future considerations

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) targeted therapy has become the standard of care for patients with EGFR-mutated metastatic non-small cell lung cancer (NSCLC) on the basis of improved prognosis and reduced toxicities compared with chemotherapy. In view of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Wenliang, Ren, Siying, Xiao, Ying, Yang, Lulu, Zeng, Chao, Hu, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712740/ https://www.ncbi.nlm.nih.gov/pubmed/36467102 http://dx.doi.org/10.3389/fphar.2022.1036334

Ejemplares similares

Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series
por: Hu, Yan, et al.
Publicado: (2022)

Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer
por: Hu, Yan, et al.
Publicado: (2022)

The predictive role of hematologic markers in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy: a retrospective cohort study
por: Liu, Wenliang, et al.
Publicado: (2023)

Current status of immunotherapy for non-small cell lung cancer
por: Yang, Tao, et al.
Publicado: (2022)

Optimization of small molecule degraders and antagonists for targeting estrogen receptor based on breast cancer: current status and future
por: Yao, Jiaqi, et al.
Publicado: (2023)

Short-Course or Total Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer - Current Status and Future Perspectives
por: Labori, Knut Jørgen
Publicado: (2022)

Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives
por: Li, Jia-Xin, et al.
Publicado: (2022)

Nutraceuticals in the Modulation of the Intestinal Microbiota: Current Status and Future Directions
por: Spisni, Enzo, et al.
Publicado: (2022)

Feiyiliu Mixture sensitizes EGFR(Del19/T790M/C797S) mutant non-small cell lung cancer to osimertinib by attenuating the PRC1/Wnt/EGFR pathway
por: Shi, Jingjing, et al.
Publicado: (2023)

Prediction of EGFR Mutation Status in Non–Small Cell Lung Cancer Based on Ensemble Learning
por: Feng, Youdan, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
por: Qian, Xiaoyu, et al.
Publicado: (2022)

Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
por: Gan, Lu, et al.
Publicado: (2022)

Immunotherapy and targeted therapy for lung cancer: Current status and future perspectives
por: Zulfiqar, Bilal, et al.
Publicado: (2022)

An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives
por: Ye, Qingmei, et al.
Publicado: (2023)

Does neoadjuvant targeted therapy provide an opportunity for resectable EGFR-mutant lung cancer: a real-world retrospective study
por: Lv, Chao, et al.
Publicado: (2020)

Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives
por: Sarkar, Chandan, et al.
Publicado: (2020)

Update on Novel Non-Operative Treatment for Osteoarthritis: Current Status and Future Trends
por: Chen, Tao, et al.
Publicado: (2021)

The Application of Inorganic Nanoparticles in Molecular Targeted Cancer Therapy: EGFR Targeting
por: Sun, Meng, et al.
Publicado: (2021)

Comparative Effectiveness of Neoadjuvant Treatments for Resectable Gastroesophageal Cancer: A Network Meta-Analysis
por: Cai, Zhaolun, et al.
Publicado: (2018)

AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer
por: Choi, Geunho, et al.
Publicado: (2021)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Patient-reported outcomes labeling for oncology drugs: Multidisciplinary perspectives on current status and future directions
por: Cella, David, et al.
Publicado: (2022)

Current status and future perspectives on neoadjuvant therapy in gastric cancer
por: Ao, Sheng, et al.
Publicado: (2021)

Neoadjuvant immunotherapy with resectable non-small cell lung cancer: recent advances and future challenges
por: Ren, Sijia, et al.
Publicado: (2020)

Platelets and platelet extracellular vesicles in drug delivery therapy: A review of the current status and future prospects
por: Dai, Zhanqiu, et al.
Publicado: (2022)

Outcomes of salvage lung resections in advanced EGFR ‐mutant lung adenocarcinomas under EGFR TKIs
por: Chen, Ying‐Yuan, et al.
Publicado: (2021)

Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients
por: Xiong, Liwen, et al.
Publicado: (2019)

Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects
por: Shi, Chunyan, et al.
Publicado: (2022)

Recent developments in nucleic acid-based therapies for Parkinson’s disease: Current status, clinical potential, and future strategies
por: Pandey, Shivam Kumar, et al.
Publicado: (2022)

The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal Cancer Patients: A Systematic Review and Meta-Analysis
por: Zhong, Xi, et al.
Publicado: (2020)

The role of peptides in reversing chemoresistance of breast cancer: current facts and future prospects
por: Huang, Yongxiu, et al.
Publicado: (2023)

Robotic single port surgery: Current status and future considerations
por: Samarasekera, Dinesh, et al.
Publicado: (2014)

Reference intervals: current status, recent developments and future considerations
por: Ozarda, Yesim
Publicado: (2016)

Current Status of Septic Cardiomyopathy: Basic Science and Clinical Progress
por: Lin, Huan, et al.
Publicado: (2020)

Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
por: Zhang, Shi-Ling, et al.
Publicado: (2023)

First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
por: Huang, Zhangfeng, et al.
Publicado: (2020)

Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models
por: Zhang, Yuhan, et al.
Publicado: (2021)

Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives
por: Godoy, Luis A., et al.
Publicado: (2023)

Editorial: Food/Diet Supplements From Natural Sources: Current Status and Future Challenges From a Pharmacological Perspective
por: Tomczyk, Michał, et al.
Publicado: (2021)

Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305
por: Zheng, Jingcao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8vm5t0sedl98siek8ahj1te7pa